Date: 2016-04-18
Type of information: Nomination
Compound:
Company: Adaptimmune Therapeutics (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 18, 2016, Adaptimmune Therapeutics announced that Dr. Wenyong Wang has joined the company as Vice President of Business Development. Prior to joining Adaptimmune, Dr. Wang was Managing Director of Investment Banking at Evolution Life Science Partners. His other former roles include Managing Director of Burrill Securities, as well as Director and Vice President positions at investment banks, Boenning & Scattergood, Inc. and Janney Montgomery Scott. In these roles, Dr. Wang leveraged his scientific expertise to provide guidance to pharmaceutical and biotech clients seeking to enhance their portfolios and grow their businesses. He completed numerous high profile licensing deals and M&A transactions over an eight year period. Before joining the investment banking industry, Dr. Wang was a principal scientist in R&D with GSK, conducting oncology and autoimmune research, and he oversaw two drug candidates from discovery through clinical development. Dr. Wang holds a PhD in Organic Chemistry from the University of Pennsylvania and an MBA from Penn State University.
Financial terms:
Latest news:
